By Fineline Cube 
Sino Biopharmaceutical Limited (HKG: 1177) announced that its independently developed LM-24C5 has received clinical trial approval from China’s National Medical Products Administration (NMPA) for conducting Phase 2 clinical trials in patients with CEACAM5-positive advanced solid tumors. The approval allows LM-24C5 to be used in combination with other anti-tumor drugs.
Drug Mechanism
LM-24C5 is a CEACAM5/4-1BB bispecific antibody that targets CEACAM5 on the surface of tumor cells and 4-1BB on the surface of immune cells. This dual targeting redirects immune cells to the tumor microenvironment, enhancing their anti-tumor activity. Preclinical studies have demonstrated that LM-24C5 can induce durable anti-tumor immune memory and exhibits synergistic effects when combined with other immunotherapeutic agents.
Potential and Current Trials
These promising results indicate LM-24C5’s potential to become a First-in-Class immunotherapy. Currently, LM-24C5 is undergoing Phase 1/2 clinical trials in the United States.-Fineline Info & Tech